Draupnir Bio

draupnir.bio

Draupnir Bio is a spin-out company from Aarhus University and the Max-Planck Society, focused on pioneering the field of extracellular targeted protein degradation. The company is developing oral, small molecule degraders of extracellular pathogenic proteins using a proprietary technology platform that targets lysosome receptors. This innovative approach aims to tackle disease-causing proteins that have been difficult to target with conventional therapies, potentially revolutionizing treatment options across multiple indications. Backed by leading European investors, Draupnir is establishing a preclinical pipeline and is positioned at the forefront of this emerging field.